


CLAIMS

1. (currently amended) A compound of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R^1 is a member selected from the group consisting of H, $\text{C}_6\text{-C}_{10}$ aryl substituted with 0-3 R^{1a} , or a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{1a} ; a $\text{C}_3\text{-C}_8$ cycloalkyl substituted with 0-2 R^{1b} , wherein said $\text{C}_3\text{-C}_8$ cycloalkyl is saturated or unsaturated; and a $\text{C}_3\text{-C}_8$ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{1c} and is saturated or unsaturated;

each R^{1a} is independently a member selected from the group consisting of H, $\text{C}_1\text{-C}_3$ perfluoroalkyl, $\text{C}_3\text{-C}_7$ cycloalkyl, F, Cl, Br, CN, NO_2 , OR^{10} , SCH_3 , S(=O)CH_3 , $\text{S(=O)}_2\text{R}^{10}$, $\text{NR}^{11}\text{R}^{12}$, acetyl, C(=O)OR^{13} , $\text{C(=O)NR}^{13}\text{R}^{14}$, $\text{S(=O)}_2\text{NR}^{13}\text{R}^{14}$, phenyl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} ; a $\text{C}_3\text{-C}_8$ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{1c} and is saturated or unsaturated; and a $\text{C}_1\text{-C}_4$ alkyl substituted with 0-2 R^{16} ;

each R^{1b} is independently a member selected from the group consisting of H, OH, F, Cl, acetyl, $=\text{O}$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, CF_3 and OCF_3 ;

each R^{1c} is independently a member selected from the group consisting of H, OH, F, Cl, $=\text{O}$, $\text{C}_1\text{-C}_6$ alkyl substituted with 0-2 R^{16} , $\text{C}_1\text{-C}_6$ alkoxy, CF_3 , OCF_3 , C(=O)R^{10} , $\text{S(=O)}_2\text{R}^{10}$, tBoe, Cbz; phenyl substituted with 0-3 R^{15} ; a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} ;

R^2 is a member selected from the group consisting of a phenyl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} ; a C_1 - C_6 alkyl substituted with 0-2 R^{2a} , wherein said C_1 - C_6 alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, and -S(=O)₂-, a C_2 - C_6 alkenyl, a C_2 - C_6 alkynyl, a C_3 - C_7 cycloalkyl substituted with 0-2 R^{19} , wherein said C_3 - C_7 cycloalkyl optionally contains a heteroatom selected from -O-, -S-, and -S(=O)₂-, and a C_7 - C_{11} bicycloalkyl substituted with 0-2 R^{19} ;

each R^{2a} is independently a member selected from the group consisting of a C_6 - C_{10} aryl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{15} ; a C_3 - C_8 cycloalkyl substituted with 0-2 R^{19} , and a C_7 - C_{11} bicycloalkyl substituted with 0-2 R^{19} ;

R^3 is a member selected from the group consisting of H and C_1 - C_4 alkyl;

subscript n is 0 or 1;

R^4 is a member selected from the group consisting of H and C_1 - C_6 alkyl;

alternatively, R^3 and R^4 are taken together to form a C_3 - C_7 cycloalkyl substituted with 0-2 R^{19} ;

R^5 is a member selected from the group consisting of H, C_3 - C_7 cycloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkyne, phenyl substituted with 0-2 R^{15} , 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} ; and a C_1 - C_6 alkyl substituted with 0-2 R^{18} , wherein said C_1 - C_6 alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷-;

Y is a member independently selected from the group consisting of a bond and $-(CR^{20}R^{21})_m-W-(CR^{22}R^{23})_p$;

subscript p is 1 or 2;

subscript m is 0 or 1;

W is a member independently selected from the group consisting of a bond, -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹²-;

X is selected from the group consisting of -C(=O)-, -OC(=O)-, -NR²⁴C(=O)- and -S(=O)₂-;

each of R⁶, R⁷, R⁸ and R⁹ is independently a member selected from the group consisting of H and C₁-C₄ alkyl;

~~alternatively, R⁵ and R⁷ are taken together to form a C₃-C₇ cycloalkyl substituted with 0-2 R¹⁹;~~

~~alternatively, R⁵ and R⁹ are taken together to form a 6-7 membered heterocyclic ring containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;~~

Ar is a member selected from the group consisting of phenyl substituted with 0-3 R²⁹, and 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R²⁹;

each R¹⁰ is independently a member selected from the group consisting of H, C₃-C₇ cycloalkyl, a C₁-C₃ perfluoroalkyl, a C₁-C₄ alkyl substituted with 0-1 R²⁵, and a phenyl substituted with 0-3 R¹⁵, ~~a 5- to 6- membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁶;~~

each R¹¹ is independently a member selected from the group consisting of H, ^tBOC, Cbz, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl)-C(=O)-, (C₁-C₆ alkyl)-S(=O)₂- and a C₁-C₆ alkyl;

each of R¹², R¹³ and R¹⁴ is independently a member selected from the group consisting of H and C₁-C₄ alkyl;

~~alternatively, R¹³ and R¹⁴ on the same N atom are taken together to form a C₃-C₇ heterocycle containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;~~

each R¹⁵ is independently a member selected from the group consisting of H, OH, F, Cl, Br, I, CN, NO₂, COOR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, acetyl, -SCH₃, -S(=O)CH₃, -S(=O)₂CH₃, NR²⁶R²⁷, C₁-C₆ alkoxy, C₁-C₆ perfluoroalkyl, C₁-C₃ perfluoroalkoxy and a C₁-C₆ alkyl;

each R¹⁶ is independently a member selected from the group consisting of H, OH, COOR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, acetyl, -SCH₃, -S(=O)CH₃, -S(=O)₂CH₃, C₁-C₆ alkoxy, NR²⁶R²⁷, and a phenyl substituted with 0-3 R¹⁵, ~~a 5- to 6- membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group~~

consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵, and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁶ and is saturated or unsaturated;

R¹⁷ is a member selected from the group consisting of H and C₁-C₄ alkyl;

each R¹⁸ is independently a member selected from the group consisting of H, OH, F, Cl, CN, NO₂, C(=O)OR³⁰, C(=O)NR¹³R¹⁴, NR¹¹R¹², a C₁-C₃ perfluoroalkyl, a C₁-C₃ perfluoroalkoxy, a phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵, a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁶ and is saturated or unsaturated; and C₃-C₈ cycloalkyl;

each R¹⁹ is a independently a member selected from the group consisting of C₁-C₄ alkyl, F, Cl and C₁-C₄ alkoxy, CF₃ and OCF₃;

alternatively, two R¹⁹ on the same carbon may be combined to form C₃-C₆ cycloalkyl;

each of R²⁰, R²¹, R²² and R²³ is independently a member selected from the group consisting of a bond, H, F, OH, C₁-C₄ alkyl, and C₁-C₃ alkylhydroxy;

alternatively, R²⁰ and R²¹ or R²² and R²³ are taken together to form a C₂-C₆ cycloalkyl;

R²⁴ is a member selected from the group consisting of H and C₁-C₄ alkyl;

each R²⁵ is independently a member selected from the group consisting of H, C₃-C₇ cycloalkyl, a phenyl substituted with 0-3 R¹⁵ and a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said 5- to 6-membered heteroaryl is substituted with 0-2 R¹⁵;

each R²⁶ is independently a member selected from the group consisting of H, C₁-C₄ alkyl, (C₁-C₄ alkyl)-C(=O)- and (C₁-C₄ alkyl)-S(=O)₂;

each R²⁷ is independently a member selected from the group consisting of H and C₁-C₄ alkyl;

alternatively, R²⁶ and R²⁷ on the same N atom are taken together to form a C₅-C₇ heterocycle containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

each R^{28} is independently a member selected from the group consisting of H, a C_1-C_6 alkyl, C_3-C_8 cycloalkyl, a phenyl substituted with 0-3 R^{15} , a benzyl substituted with 0-2 R^{15} ;

each R^{29} is independently a member selected from the group consisting of H, F, Cl, Br, I, CN, NO_2 , OR^{28} , SR^{28} , $S(=O)R^{28}$, $S(=O)_2R^{28}$, $S(=O)_2NR^{13}R^{14}$, $NR^{26}R^{27}$, acetyl, $C(=O)NR^{13}R^{14}$, $C(=O)OR^{13}$, C_1-C_6 alkyl, $OCHF_2$, SCF_3 , OCF_3 , and $-C(=NH)NH_2$; and 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S;

alternatively, two R^{29} -substituted on adjacent atoms may be combined to form a 5- to 6-membered heterocyclic fused radical, wherein said 5- to 6-membered heterocyclic fused radical comprise 1 or 2 heteroatom(s) selected from O, S and N; wherein said 5- to 6-membered heterocyclic fused radical is substituted with 0-1 oxo;

alternatively, R^{29} and R^9 are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R^{19} ;

each R^{30} is independently a member selected from the group consisting of H, C_3-C_7 cycloalkyl, C_1-C_4 alkyl substituted with 0-1 R^{25} , and a phenyl substituted with 0-3 R^{15} ; and a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S; wherein said heteroaryl is substituted with 0-3 R^{15} ;


and with the proviso that R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 are not all hydrogen.

2-3. (canceled)

4. (currently amended) The compound of claim 1, wherein: R^1 is a member selected from the group consisting of phenyl substituted with 0-3 R^{1a} ; furanyl substituted with 0-3 R^{1a} ; C_2-C_6 cycloalkyl substituted with 0-3 R^{1a} ; indolyl substituted with 0-3 R^{1a} ; 5- or 6-membered heterocyclic substituted with 0-3 R^{1a} ; pyridazinyl substituted with 0-3 R^{1a} ; imidazolyl substituted with 0-3 R^{1a} ; thienyl substituted with 0-3 R^{1a} ; thiazolyl substituted with 0-3 R^{1a} ; oxadiazolyl substituted with 0-3 R^{1a} ; pyrazolyl substituted with 0-3 R^{1a} ; isoxazolyl substituted with 0-3 R^{1a} ; tetrazolyl substituted with 0-3 R^{1a} ; oxazolyl substituted with 0-3 R^{1a} ; and pyridyl substituted with 0-3 R^{1a} .

5-6. (canceled)

7. (currently amended) The compound of claim 1, according to formula Ia:



wherein:

~~R¹ is a member selected from the group consisting of a C₃-C₈ cycloalkyl substituted with 0-2 R^{1b}, wherein said C₃-C₈ cycloalkyl is saturated or unsaturated and a C₃-C₇ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{1e} and is saturated or unsaturated;~~

R² is a member selected from the group consisting of a phenyl substituted with 0-3 R¹⁵, ~~a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵~~; a C₁-C₆ alkyl substituted with 0-2 R^{2a}, and a C₃-C₇ cycloalkyl substituted with 0-2 R¹⁹; and

Ar is phenyl substituted with 0-3 R²⁹, or alternatively, R²⁹ and R⁹ are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R¹⁹.

8. (currently amended) The compound of claim 7, wherein:

R² is a member selected from the group consisting of a C₁-C₂ alkyl substituted with 1 R^{2a}, and C₁-C₆ alkyl;


each R^{2a} is independently a member selected from the group consisting of a phenyl substituted with 0-3 R¹⁵, and a C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹;

R⁵ is a member selected from the group consisting of H, C₃-C₇ cycloalkyl; a C₁-C₆ alkyl substituted with 0-1 R¹⁸, wherein said C₁-C₆ alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷; and


each R¹⁸ is independently a member selected from the group consisting of H, OH, F, Cl, CN, C(=O)OR³⁰, C(=O)NR¹³R¹⁴, NR¹¹R¹², a phenyl substituted with 0-3 R¹⁵, ~~a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the~~

group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁵ and is saturated or unsaturated; and C₃-C₈ cycloalkyl.

9. (currently amended) The compound of claim 7, wherein said compound is of the formula:



10. (withdrawn, currently amended) The compound of claim 1, according to formula Ic:



wherein:

R¹ is a member selected from the group consisting of tBu, phenyl substituted with 0-2 R¹⁵, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, and a C₄-C₇ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁶;

each R¹⁶ is independently a member selected from the group consisting of H, OH, F, Cl, =O, C₁-C₆ alkyl substituted with 0-2 R¹⁶, a C₁-C₆ alkoxy, CF₃, OCF₃, C(=O)R¹⁰, S(=O)₂R¹⁰, tBoc, Cbz, phenyl substituted with 0-3 R¹⁵, and a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵;

Y is a member independently selected from the group consisting of a bond and (CR²⁰R²¹)_m-W-(CR²²R²³)_p, wherein m is 0, W is a bond, and R²²R²³ are both H;

R² is a member selected from the group consisting of a phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said

heteroaryl is substituted with 0-2 R¹⁵, a C₁-C₆ alkyl, a C₁-C₃ alkyl substituted with 1 R^{2a}, and a C₃-C₇ cycloalkyl substituted with 0-2 R¹⁹;

each R^{2a} is independently a member selected from the group consisting of a C₆-C₁₀ aryl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵; a C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹, and a C₇-C₁₁ bicycloalkyl substituted with 0-2 R¹⁹; and

Ar is phenyl substituted with 0-3 R²⁹, or alternatively, R²⁹ and R⁹ are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R¹⁹.

11. (withdrawn, currently amended) The compound of claim 10, wherein:


R² is a member selected from the group consisting of a C₁-C₂ alkyl substituted with 1 R^{2a}, and C₁-C₆ alkyl;

each R^{2a} is independently a member selected from the group consisting of a phenyl substituted with 0-3 R¹⁵, and a C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹;


R⁵ is a member selected from the group consisting of H, C₃-C₇ cycloalkyl; a C₁-C₆ alkyl substituted with 0-1 R¹⁸, wherein said C₁-C₆ alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷-; and

each R¹⁸ is independently a member selected from the group consisting of H, OH, F, Cl, CN, C(=O)OR³⁰, C(=O)NR¹³R¹⁴, NR¹¹R¹², a phenyl substituted with 0-3 R¹⁵, a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁵ and is saturated or unsaturated; and C₃-C₈ cycloalkyl.

12. (withdrawn, currently amended) The compound of claim 10, wherein said compound is of the formula:



13. (withdrawn, currently amended) The compound of claim 1, according to formula Id:



wherein:

R¹ is a member selected from the group consisting of methyl, benzyl, C₆-C₁₀ aryl substituted with 0-3 R^{1a}, and a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{1a};

each R^{1a} is independently a member selected from the group consisting of H, C₁-C₃ perfluoroalkyl, C₃-C₇ cycloalkyl, F, Cl, Br, CN, NO₂, OR¹⁰, SCH₃, S(=O)CH₃, S(=O)₂R¹⁰, NR¹¹R¹², acetyl, C(=O)OR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, and phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, and a C₁-C₄ alkyl; and

Ar is phenyl substituted with 0-3 R²⁰, or alternatively, R²⁰ and R⁹ are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R¹⁹.

14. (withdrawn, currently amended) The compound of claim 13, wherein:

R² is a member selected from the group consisting of a C₁-C₂ alkyl substituted with 1 R^{2a}, and C₁-C₆ alkyl;


each R^{2a} is independently a member selected from the group consisting of a phenyl substituted with 0-3 R¹⁵, and a C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹;

R⁵ is a member selected from the group consisting of H, C₃-C₇ cycloalkyl; a C₁-C₆ alkyl substituted with 0-1 R¹⁸, wherein said C₁-C₆ alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷-; and


each R¹⁸ is independently a member selected from the group consisting of H, OH, F, Cl, CN, C(=O)OR³⁰, C(=O)NR¹³R¹⁴, NR¹¹R¹², a phenyl substituted with 0-3 R¹⁵, a C₄-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the

group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁵ and is saturated or unsaturated; and C₃-C₈ cycloalkyl.

15. (withdrawn) The compound of claim 13, wherein said compound is of the formula:



16. (currently amended) The compound of claim 1, according to formula Ic



wherein:

R¹ is a member selected from the group consisting of a C₆-C₁₀ aryl substituted with 0-3 R^{1a}, a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1- to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{1a};

each R^{1a} is independently a member selected from the group consisting of H, C₁-C₃ perfluoroalkyl, C₃-C₇ cycloalkyl, F, Cl, Br, CN, NO₂, OR¹⁰, SCH₃, S(=O)CH₃, S(=O)₂R¹⁰, NR¹¹R¹², acetyl, C(=O)OR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic heteroaryl containing 1- to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, a C₃-C₈ heterocycle containing 1- to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁶ and is saturated or unsaturated, and a C₁-C₄ alkyl substituted with 0-2 R¹⁶; and

Ar is phenyl substituted with 0-3 R²⁹, or alternatively, R²⁹ and R⁹ are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R¹⁹.


17. (original) The compound of claim 16, wherein:

R^2 is a member selected from the group consisting of a C_1 - C_2 alkyl substituted with 1 R^{2a} , and C_1 - C_6 alkyl;


each R^{2a} is independently a member selected from the group consisting of a phenyl substituted with 0-3 R^{15} , and a C_3 - C_8 cycloalkyl substituted with 0-2 R^{19} ; and

R^3 is a member selected from the group consisting of H, C_3 - C_7 cycloalkyl; a C_1 - C_6 alkyl, wherein said C_1 - C_6 alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷-.

18. (currently amended) The compound of claim 16, wherein said compound is of the formula:



19. (currently amended) The compound of claim 1, according to formula Ia



wherein:

R^1 is a member selected from the group consisting of C_6 - C_{10} aryl substituted with 0-3 R^{1a} , and a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{1a} ;

each R^{1a} is independently a member selected from the group consisting of H, C_1 - C_3 perfluoroalkyl, C_3 - C_7 cycloalkyl, F, Cl, Br, CN, NO₂, OR¹⁰, SCH₃, S(=O)CH₃, S(=O)₂R¹⁰, NR¹¹R¹², acetyl, C(=O)OR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, phenyl substituted with 0-3 R^{15} ; and a C_1 - C_4 alkyl substituted with 0-2 R^{16} ;


R^2 is a member selected from the group consisting of a phenyl substituted with 0-3 R^{15} ; a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said

heteroaryl is substituted with 0-2 R¹⁵, a C₁-C₆ alkyl, a C₁-C₂ alkyl substituted with 1 R^{2a}, and a C₃-C₇ cycloalkyl substituted with 0-2 R¹⁹;

each R^{2a} is independently a member selected from the group consisting of a C₆-C₁₀ aryl substituted with 0-3 R¹⁵; a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵; a C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹; and a C₇-C₁₁ bicycloalkyl substituted with 0-2 R¹⁹; and


Ar is phenyl substituted with 0-3 R²⁹, or alternatively, R²⁹ and R⁹ are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R¹⁹.

20. (currently amended) The compound of claim 19, wherein said compound is of the formula:



21-22. (canceled)

23. (currently amended) The compound of claim 1, according to formula Ig:




Ig

wherein:

R⁵ is a member selected from the group consisting of H, C₃-C₇ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkyne, phenyl substituted with 0-2 R¹⁵; 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵; and a C₁-C₆

alkyl substituted with 0-2 R¹⁸, wherein said C₁-C₆ alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷-.


24. (currently amended) The compound of claim 23, according to formula Ih:



25. (original) The compound of claim 1, wherein R⁹ is H; and Ar is phenyl substituted with 0-3 R²⁹, or alternatively, R²⁹ and R⁹ are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5- to 7-membered fused heterocyclic ring is substituted with 0-2 R¹⁹.

26. (canceled)

27. (currently amended) A pharmaceutical composition comprising ~~a~~ the compound of Formula I in claim 1:



I

or a pharmaceutically acceptable salt and an excipient, or prodrug thereof;
 wherein:

R¹ is a member selected from the group consisting of H, C₆-C₁₀ aryl substituted with 0-3 R^{1a}, a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{1a}; a C₃-C₈ cycloalkyl substituted with 0-2 R^{1b}, wherein said C₃-C₈ cycloalkyl is saturated or unsaturated; and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{1c} and is saturated or unsaturated;

each R^{10} is independently a member selected from the group consisting of H, C_1-C_3 perfluoroalkyl, C_3-C_7 cycloalkyl, F, Cl, Br, CN, NO_2 , OR^{10} , SCH_3 , $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{14}R^{13}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{12}R^{14}$, phenyl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} , a C_3-C_8 heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{16} and is saturated or unsaturated, and a C_4-C_4 alkyl substituted with 0-2 R^{16} ;

each R^{1b} is independently a member selected from the group consisting of H, OH, F, Cl, acetyl, $=O$, C_1-C_6 alkyl, C_1-C_6 alkoxy, CF_3 and OCF_3 ;

each R^{1c} is independently a member selected from the group consisting of H, OH, F, Cl, $=O$, C_1-C_6 alkyl substituted with 0-2 R^{16} , C_1-C_6 alkoxy, CF_3 , OCF_3 , $C(=O)R^{10}$, $S(=O)_2R^{10}$, tBoc, Cbz, phenyl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} ;

R^2 is a member selected from the group consisting of a phenyl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R^{15} , a C_4-C_6 alkyl substituted with 0-2 R^{2a} , wherein said C_4-C_6 alkyl optionally contains a heteroatom selected from the group consisting of O, S, and $S(=O)_2$, a C_2-C_6 alkenyl, a C_2-C_6 alkynyl, a C_3-C_7 cycloalkyl substituted with 0-2 R^{10} , wherein said C_3-C_7 cycloalkyl optionally contains a heteroatom selected from O, S, and $S(=O)_2$, and a C_2-C_{14} bicycloalkyl substituted with 0-2 R^{10} ;

each R^{2a} is independently a member selected from the group consisting of a C_6-C_{10} aryl substituted with 0-3 R^{15} , a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{15} , a C_3-C_8 cycloalkyl substituted with 0-2 R^{10} , and a C_7-C_{14} bicycloalkyl substituted with 0-2 R^{10} ;

R^3 is a member selected from the group consisting of H and C_1-C_4 alkyl;
 subscript n is 0 or 1;

R^4 is a member selected from the group consisting of H and C_1-C_6 alkyl;

alternatively, R^2 and R^4 are taken together to form a C_3 - C_7 cycloalkyl substituted with $0-2 R^{19}$;

R^5 is a member selected from the group consisting of H, C_3 - C_7 cycloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkyne, phenyl substituted with $0-2 R^{15}$; 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with $0-2 R^{15}$; a C_4 - C_6 alkyl substituted with $0-2 R^{16}$; wherein said C_4 - C_6 alkyl optionally contains a heteroatom selected from the group consisting of O, S, $S(=O)$, $S(=O)_2$ and NR^{17} ;

Y is a member independently selected from the group consisting of a bond and $-(CR^{20}R^{21})_m-W-(CR^{22}R^{23})_p$;

subscript p is 1 or 2;

subscript m is 0 or 1;

W is a member independently selected from the group consisting of a bond, O, S, $S(=O)$, $S(=O)_2$ and NR^{12} ;

X is selected from the group consisting of $C(=O)$, $OC(=O)$, $NR^{24}C(=O)$ and $S(=O)_2$;

each of R^6 , R^7 , R^8 and R^9 is independently a member selected from the group consisting of H and C_1 - C_4 alkyl;

alternatively, R^5 and R^7 are taken together to form a C_3 - C_7 cycloalkyl substituted with $0-2 R^{19}$;

alternatively, R^5 and R^9 are taken together to form a 6-7 membered heterocyclic ring containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

Ar is a member selected from the group consisting of phenyl substituted with $0-3 R^{20}$; and 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with $0-3 R^{20}$;

each R^{10} is independently a member selected from the group consisting of H, C_2 - C_4 cycloalkyl, a C_4 - C_7 perfluoroalkyl, a C_4 - C_4 alkyl substituted with $0-1 R^{25}$; a phenyl substituted with $0-3 R^{15}$; a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with $0-2 R^{15}$; and a C_3 - C_8 heterocycle containing 1 to 2 heteroatoms

each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{1c};

each R¹¹ is independently a member selected from the group consisting of H, 'BOC, Cbz, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C(=O), (C₁-C₆ alkyl) S(=O)₂ and a C₁-C₆ alkyl;

each of R¹², R¹³ and R¹⁴ is independently a member selected from the group consisting of H and C₁-C₄ alkyl;

alternatively, R¹³ and R¹⁴ on the same N atom are taken together to form a C₅-C₂ heterocycle containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

each R¹⁵ is independently a member selected from the group consisting of H, OH, F, Cl, Br, I, CN, NO₂, COOR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, acetyl, SCH₃, S(=O)CH₃, S(=O)₂CH₃, NR²⁶R²⁷, C₁-C₆ alkoxy, C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy and a C₁-C₆ alkyl;

each R¹⁶ is independently a member selected from the group consisting of H, OH, COOR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, acetyl, SCH₃, S(=O)CH₃, S(=O)₂CH₃, C₁-C₆ alkoxy, NR²⁶R²⁷, a phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵, and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁵ and is saturated or unsaturated;

R¹⁷ is a member selected from the group consisting of H and C₁-C₄ alkyl;

each R¹⁸ is independently a member selected from the group consisting of H, OH, F, Cl, CN, NO₂, C(=O)OR³⁰, C(=O)NR¹³R¹⁴, NR⁴⁴R⁴², a C₁-C₃ perfluoroalkyl, a C₁-C₃ perfluoroalkoxy, a phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵, a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁵ and is saturated or unsaturated; and C₃-C₈ cycloalkyl;

each R¹⁰ is a member selected from the group consisting of C₁-C₄ alkyl, F, Cl and C₁-C₄ alkoxy, CF₃ and OCF₃;

alternatively, two R¹⁰ on the same carbon may be combined to form C₃-C₆ cycloalkyl;

each of R^{20} , R^{21} , R^{22} and R^{23} is independently a member selected from the group consisting of a bond, H, F, OH, C_1-C_4 alkyl, and C_1-C_3 alkylhydroxy;

alternatively, R^{20} and R^{21} or R^{22} and R^{23} are taken together to form a C_3-C_6 cycloalkyl;

R^{24} is a member selected from the group consisting of H and C_1-C_4 alkyl;

each R^{25} is independently a member selected from the group consisting of H, C_3-C_7 cycloalkyl, a phenyl substituted with 0-3 R^{15} , and a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said 5- to 6-membered heteroaryl is substituted with 0-2 R^{15} ;

each R^{26} is independently a member selected from the group consisting of H, C_1-C_4 alkyl, $(C_1-C_4\text{ alkyl})C(=O)-$ and $(C_1-C_4\text{ alkyl})S(=O)_2-$;

each R^{27} is independently a member selected from the group consisting of H and C_1-C_4 alkyl;

alternatively, R^{26} and R^{27} on the same N atom are taken together to form a C_5-C_8 heterocycle containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

each R^{28} is independently a member selected from the group consisting of H, a C_1-C_6 alkyl, C_3-C_6 cycloalkyl, a phenyl substituted with 0-3 R^{15} , a benzyl substituted with 0-2 R^{15} ;

each R^{29} is independently a member selected from the group consisting of H, F, Cl, Br, I, CN, NO_2 , OR^{28} , SR^{28} , $S(=O)R^{28}$, $S(=O)_2R^{28}$, $S(=O)_2NR^{13}R^{14}$, $NR^{26}R^{27}$, acetyl, $C(=O)NR^{13}R^{14}$, $C(=O)OR^{13}$, C_1-C_6 alkyl, $OCHF_2$, SCF_3 , OCF_3 , $C(=NH)NH_2$, and 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S;

alternatively, two R^{29} substituted on adjacent atoms may be combined to form a 5 to 6 membered heterocyclic fused radical, wherein said 5 to 6 membered heterocyclic fused radical comprise 1 or 2 heteroatom(s) selected from O, S and N; wherein said 5 to 6 membered heterocyclic fused radical is substituted with 0-1 oxo;


alternatively, R^{20} and R^{29} are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5 to 7 membered fused heterocyclic ring is substituted with 0-2 R^{10} ;

each R^{30} is independently a member selected from the group consisting of H, C_1-C_7 cycloalkyl, C_1-C_4 alkyl substituted with 0-1 R^{25} , a phenyl substituted with 0-3 R^{15} , and a 5- to

6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵; with the proviso that R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are not all hydrogen; and an exception.

28. (currently amended) ~~A pharmaceutical~~ The composition comprising the compound of claim 38 of claim 27, wherein said compound is a member selected from the compounds of Table I.

29. (withdrawn) A method of selectively inhibiting cathepsin S activity in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound of Formula I:



I

or a pharmaceutically acceptable salt or prodrug thereof,
 wherein:

R¹ is a member selected from the group consisting of H, C₆-C₁₀ aryl substituted with 0-3 R^{1a}, a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{1a}, a C₃-C₈ cycloalkyl substituted with 0-2 R^{1b}, wherein said C₃-C₈ cycloalkyl is saturated or unsaturated; and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{1c} and is saturated or unsaturated;

each R^{1a} is independently a member selected from the group consisting of H, C₁-C₃ perfluoroalkyl, C₃-C₇ cycloalkyl, F, Cl, Br, CN, NO₂, OR¹⁰, SCH₃, S(=O)CH₃, S(=O)₂R¹⁰, NR¹¹R¹², acetyl, C(=O)OR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said

heterocycle is substituted with 0-2 R^{1c} and is saturated or unsaturated, and a C₁-C₄ alkyl substituted with 0-2 R¹⁶;

each R^{1b} is independently a member selected from the group consisting of H, OH, F, Cl, acetyl, =O, C₁-C₆ alkyl, C₁-C₆ alkoxy, CF₃ and OCF₃;

each R^{1c} is independently a member selected from the group consisting of H, OH, F, Cl, =O, C₁-C₆ alkyl substituted with 0-2 R¹⁶, C₁-C₆ alkoxy, CF₃, OCF₃, C(=O)R¹⁰, S(=O)₂R¹⁰, tBoc, Cbz; phenyl substituted with 0-3 R¹⁵; a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵;

R² is a member selected from the group consisting of a phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, a C₁-C₆ alkyl substituted with 0-2 R^{2a}, wherein said C₁-C₆ alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, and -S(=O)₂-, a C₂-C₆ alkenyl, a C₂-C₆ alkynyl, a C₃-C₇ cycloalkyl substituted with 0-2 R¹⁹, wherein said C₃-C₇ cycloalkyl optionally contains a heteroatom selected from -O-, -S-, and -S(=O)₂-, and a C₇-C₁₁ bicycloalkyl substituted with 0-2 R¹⁹;

each R^{2a} is independently a member selected from the group consisting of a C₆-C₁₀ aryl substituted with 0-3 R¹⁵, a 5- to 6-membered monocyclic or 8- to 10-membered bicyclic heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R¹⁵, a C₃-C₈ cycloalkyl substituted with 0-2 R¹⁹, and a C₇-C₁₁ bicycloalkyl substituted with 0-2 R¹⁹;

R³ is a member selected from the group consisting of H and C₁-C₄ alkyl;

subscript n is 0 or 1;

R⁴ is a member selected from the group consisting of H and C₁-C₆ alkyl;

alternatively, R² and R⁴ are taken together to form a C₅-C₇ cycloalkyl substituted with 0-2 R¹⁹;

R⁵ is a member selected from the group consisting of H, C₃-C₇ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkyne, phenyl substituted with 0-2 R¹⁵; 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, a C₁-C₆ alkyl substituted with 0-2 R¹⁸, wherein said C₁-C₆ alkyl optionally contains a heteroatom selected from the group consisting of -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹⁷-;

Y is a member independently selected from the group consisting of a bond and $-(CR^{20}R^{21})_m-W-(CR^{22}R^{23})_p-$;

subscript p is 1 or 2;

subscript m is 0 or 1;

W is a member independently selected from the group consisting of a bond, -O-, -S-, -S(=O)-, -S(=O)₂- and -NR¹²-;

X is selected from the group consisting of -C(=O)-, -OC(=O)-, -NR²⁴C(=O)- and -S(=O)₂-;

each of R⁶, R⁷, R⁸ and R⁹ is independently a member selected from the group consisting of H and C₁-C₄ alkyl;

alternatively, R⁵ and R⁷ are taken together to form a C₅-C₇ cycloalkyl substituted with 0-2 R¹⁹;

alternatively, R⁵ and R⁹ are taken together to form a 6-7 membered heterocyclic ring containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

Ar is a member selected from the group consisting of phenyl substituted with 0-3 R²⁹, and 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R²⁹;

each R¹⁰ is independently a member selected from the group consisting of H, C₃-C₇ cycloalkyl, a C₁-C₃ perfluoroalkyl, a C₁-C₄ alkyl substituted with 0-1 R²⁵, a phenyl substituted with 0-3 R¹⁵, a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-2 R¹⁵, and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R¹⁶;

each R¹¹ is independently a member selected from the group consisting of H, ^tBOC, Cbz, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl)-C(=O)-, (C₁-C₆ alkyl)-S(=O)₂- and a C₁-C₆ alkyl;

each of R¹², R¹³ and R¹⁴ is independently a member selected from the group consisting of H and C₁-C₄ alkyl;

alternatively, R¹³ and R¹⁴ on the same N atom are taken together to form a C₅-C₇ heterocycle containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

each R^{15} is independently a member selected from the group consisting of H, OH, F, Cl, Br, I, CN, NO₂, COOR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, acetyl, -SCH₃, -S(=O)CH₃, -S(=O)₂CH₃, NR²⁶R²⁷, C₁-C₆ alkoxy, C₁-C₃ perfluoroalkyl, C₁-C₃ perfluoroalkoxy and a C₁-C₆ alkyl;

each R^{16} is independently a member selected from the group consisting of H, OH, COOR¹³, C(=O)NR¹³R¹⁴, S(=O)₂NR¹³R¹⁴, acetyl, -SCH₃, -S(=O)CH₃, -S(=O)₂CH₃, C₁-C₆ alkoxy, NR²⁶R²⁷, a phenyl substituted with 0-3 R^{15} , a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{15} , and a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{15} and is saturated or unsaturated;

R^{17} is a member selected from the group consisting of H and C₁-C₄ alkyl;

each R^{18} is independently a member selected from the group consisting of H, OH, F, Cl, CN, NO₂, C(=O)OR³⁰, C(=O)NR¹³R¹⁴, NR¹¹R¹², a C₁-C₃ perfluoroalkyl, a C₁-C₃ perfluoroalkoxy, a phenyl substituted with 0-3 R^{15} , a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{15} , a C₃-C₈ heterocycle containing 1 to 2 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heterocycle is substituted with 0-2 R^{15} and is saturated or unsaturated; and C₃-C₈ cycloalkyl;

each R^{19} is independently a member selected from the group consisting of C₁-C₄ alkyl, F, Cl and C₁-C₄ alkoxy, CF₃ and OCF₃;

alternatively, two R^{19} on the same carbon may be combined to form C₃-C₆ cycloalkyl; each of R^{20} , R^{21} , R^{22} and R^{23} is independently a member selected from the group consisting of a bond, H, F, OH, C₁-C₄ alkyl, and C₁-C₃ alkylhydroxy;

alternatively, R^{20} and R^{21} or R^{22} and R^{23} are taken together to form a C₃-C₆ cycloalkyl;

R^{24} is a member selected from the group consisting of H and C₁-C₄ alkyl;

each R^{25} is independently a member selected from the group consisting of H, C₃-C₇ cycloalkyl, a phenyl substituted with 0-3 R^{15} and a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said 5- to 6-membered heteroaryl is substituted with 0-2 R^{15} ;

each R^{26} is independently a member selected from the group consisting of H, C_1 - C_4 alkyl, $(C_1$ - C_4 alkyl)- $C(=O)$ - and $(C_1$ - C_4 alkyl)- $S(=O)_2$;

each R^{27} is independently a member selected from the group consisting of H and C_1 - C_4 alkyl;

alternatively, R^{26} and R^{27} on the same N atom are taken together to form a C_5 - C_7 heterocycle containing 1-2 heteroatoms each independently a member selected from the group consisting of N, O and S;

each R^{28} is independently a member selected from the group consisting of H, a C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, a phenyl substituted with 0-3 R^{15} , a benzyl substituted with 0-2 R^{15} ;

each R^{29} is independently a member selected from the group consisting of H, F, Cl, Br, I, CN, NO_2 , OR^{28} , SR^{28} , $S(=O)R^{28}$, $S(=O)_2R^{28}$, $S(=O)_2NR^{13}R^{14}$, $NR^{26}R^{27}$, acetyl, $C(=O)NR^{13}R^{14}$, $C(=O)OR^{13}$, C_1 - C_6 alkyl, $OCHF_2$, SCF_3 , OCF_3 , $-C(=NH)NH_2$, and 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S;

alternatively, two R^{29} substituted on adjacent atoms may be combined to form a 5 to 6 membered heterocyclic fused radical, wherein said 5 to 6 membered heterocyclic fused radical comprise 1 or 2 heteroatom(s) selected from O, S and N; wherein said 5 to 6 membered heterocyclic fused radical is substituted with 0-1 oxo;

alternatively, R^{29} and R^9 are taken together to form a 5- to 7-membered fused heterocyclic ring containing 1-2 heteroatom(s) each independently a member selected from the group consisting of N, O and S; wherein said 5 to 7 membered fused heterocyclic ring is substituted with 0-2 R^{19} ;

each R^{30} is independently a member selected from the group consisting of H, C_3 - C_7 cycloalkyl, C_1 - C_4 alkyl substituted with 0-1 R^{25} , a phenyl substituted with 0-3 R^{15} , and a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms each independently a member selected from the group consisting of N, O and S, wherein said heteroaryl is substituted with 0-3 R^{15} ;

and with the proviso that R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 are not all hydrogen.

30. (withdrawn) The method of claim 29, wherein the cathepsin S inhibition constant for a compound of Formula I is less than 10 μ M.

31. (withdrawn) The method of claim 30, wherein the cathepsin S inhibition constant for a compound of Formula I is less than 1.0 μ M.

32. (withdrawn) The method of claim 31, wherein the cathepsin S inhibition constant for a compound of Formula I is less than 0.1 μ M.

33. (withdrawn) The method of claim 29, wherein cathepsin S is selectively inhibited in the presence of at least one other cathepsin.

34. (withdrawn) The method of claim 33, wherein the inhibition constant of a compound of Formula I for said at least one other cathepsin is at least 10 times greater than a cathepsin S inhibition constant of a compound of Formula I.

35. (withdrawn) The method of claim 34, wherein the inhibition constant of a compound of Formula I for said at least one other cathepsin is at least 100 times greater than said cathepsin S inhibition constant of a compound of Formula I.

36. (withdrawn) The method of claim 35, wherein the inhibition constant of a compound of Formula I for said at least one other cathepsin is at least 1000 times greater than said cathepsin S inhibition constant of a compound of Formula I.

37. (withdrawn) The method of claim 29, wherein said compound is a member selected from the compounds of Table I.

38. (new) The compound of claim 1, selected from the group consisting of:

(S)-N-(1-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-methyl-butyl)-3-methyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-phenoxy-benzamide;

(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-[2-(4-methoxy-phenyl)-acetyl-amino]-propionamide;

(S)-N-(1-[2-(5-Chloro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-methyl-butyl)-3-methyl-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(7-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(6-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(7-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-cyano-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

Cyclopropanecarboxylic acid (S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-amide;

(S)-N-{3-Cyclohexyl-1-[2-(4-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-benzyloxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

N-{1-(S)-[2-(4-Methoxy-phenylamino)-propylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-{1-(S)-[2-(4-Methoxy-phenylamino)-1-methyl-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-{1-(S)-[2-(4-Methoxy-phenylamino)-1-(S)-methyl-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-{1-(S)-[2-(4-Methoxy-phenylamino)-1-(R)-methyl-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-{2-Cyclohexyl-(1S)-[2-(4-methoxy-phenylamino)-(1R)-methyl-ethylcarbamoyl]-ethyl}-3-methoxy-benzamide;

N-{(1S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1,1-dimethyl-ethylcarbamoyl]-2-phenyl-ethyl}-3-methyl-benzamide;

N-{1-(S)-[1-(R)-Benzyloxymethyl-2-(4-methoxy-phenylamino)-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-(S)-[1-(R)-Benzyloxymethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-phenyl-methyl}-3-methoxy-benzamide;

N-[1-(*S*)-[1-(*R*)-Benzyloxymethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-2-(4-fluoro-phenyl)-ethyl]-3-methoxy-benzamide;

N-[1-(*S*)-[(2-Benzyloxy-1-(*R*)-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-ethylcarbamoyl]-3-cyclohexyl-propyl]-3-methoxy-benzamide;

N-[3-Cyclohexyl-1-(*S*)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(*R*)-hydroxymethyl-ethylcarbamoyl]-propyl]-3-methoxy-benzamide;

N-[3-Cyclohexyl-1-(*R*)-[(*S*)-2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(*R*)-hydroxymethyl-ethylcarbamoyl]-propyl]-3-methoxy-benzamide;

(*S,S*)-5-(5-Fluoro-2,3-dihydro-indol-1-yl)-4-[4-methyl-2-(3-methyl-benzoylamino)-pentanoylamino]-pentanoic acid benzyl ester;

(*S,S*)-5-(5-Fluoro-2,3-dihydro-indol-1-yl)-4-[4-methyl-2-(3-methyl-benzoylamino)-pentanoylamino]-pentanoic acid;

(*S,S*)-*N*-[1-[3-Carbamoyl-1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-propylcarbamoyl]-3-methyl-butyl]-3-methyl-benzamide;

(*S,S*)-*N*-[1-[1-(5-Fluoro-2,3-dihydro-indol-1-ylmethyl)-3-ureido-propylcarbamoyl]-3-methyl-butyl]-3-methyl-benzamide;

(*S,S*)-3-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

(*S,S*)-3-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

(*S,S*)-*N*-[1-[1-Benzyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-cyclohexyl-propyl]-3-methoxy-benzamide;

(*S,S*)-*N*-[3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-3-methyl-butylcarbamoyl]-propyl]-3-methoxy-benzamide;

(*S,S*)-*N*-[3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-2-methyl-propylcarbamoyl]-propyl]-3-methoxy-benzamide;

(*S,S*)-*N*-[3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-phenyl-ethylcarbamoyl]-propyl]-3-methoxy-benzamide;

N-[1-(*S*)-[2-(*R*)-Benzyloxy-1-(*R*)-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-propylcarbamoyl]-3-cyclohexyl-propyl]-3-methoxy-benzamide;

N-[1-(*R*)-[1-(*R*)-Benzylsulfanylmethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-cyclohexyl-propyl]-3-methoxy-benzamide;

(S,S)-[5-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-6-(5-fluoro-2,3-dihydro-indol-1-yl)-hexyl]-carbamic acid benzyl ester;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(2-fluoro-biphenyl-4-yl)-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-p-tolyl-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-o-tolyl-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(4-fluoro-phenyl)-propionamide;

2-(4-Chloro-phenyl)-N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(R)-phenyl-propionamide;

N-(S)-[2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl]-3-methyl-benzamide;

N-(S)-[2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl]-4-(methanesulfonylamino-methyl)-benzamide;

N-(S)-[2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl]-3-methanesulfonyl-benzamide;

N-(S)-[2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl]-4-methanesulfonylamino-benzamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(4-hydroxy-phenyl)-propionamide;

4-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(S)-(2-(R)-phenyl-propionylamino)-butyramide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(R)-phenyl-butyramide;

N-{1-(S)-[1-(R)-Benzyloxymethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-2-cyclohexyl-ethyl}-3-methoxy-benzamide;

N-{2-Cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-ethyl}-3-methoxy-benzamide;

N-{1-(S)-[1-(R)-Benzyloxymethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

N-{1-(S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

3-(S)-(2-(S)-Benzyloxycarbonylamino-4,4-dimethyl-pentanoylamino)-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid tert-butyl ester;

3-(S)-(2-(S)-Benzyloxycarbonylamino-4,4-dimethyl-pentanoylamino)-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-(S)-[2-(S)-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid tert-butyl ester;

3-(S)-[3-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-propionylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

3-(S)-[3-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-propionylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-(S)-[2-(S)-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid ethyl ester;

N-{1-(S)-[2-Cyano-1-(S)-(5-fluoro-2,3-dihydro-indol-1-yl)methyl]-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

N-{1-(S)-[5-Amino-1-(S)-(5-fluoro-2,3-dihydro-indol-1-yl)methyl]-pentylcarbamoyl]-3-cyclohexyl-propyl}-3-methoxy-benzamide;

3-(S)-(2-(S)-Benzyloxycarbonylamino-3-cyclohexyl-propionylamino)-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

1-(S)-[1-(R)-Benzyloxymethyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-2-cyclohexyl-ethyl]-carbamic acid benzyl ester;

N-{3-Cyclohexyl-1-(S)-[2-(3,5-dimethoxy-benzyloxy)-1-(R)-(5-fluoro-2,3-dihydro-indol-1-yl)methyl]-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

4-[2-(R)-[4-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-butyrylamino]-3-(5-fluoro-2,3-dihydro-indol-1-yl)-propoxymethyl]-benzoic acid methyl ester;

(S,S)-N-[3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(4-hydroxy-benzyl)-ethylcarbamoyl]-propyl]-3-methoxy-benzamide;

{2-Cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(S)-methyl-ethylcarbamoyl]-ethyl]-carbamic acid benzyl ester;

4-Benzoyloxy-N--(*R,S*)-{[2-(4-amidinophenylamino)-1-(*S*)-methyl-ethylcarbamoyl]-(2,4-dichloro-phenyl)-methyl}-benzamide;
{1-(*S*)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1-(*S*)-methyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-carbamic acid benzyl ester;
Cyclopropanecarboxylic acid {1-(*S*)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(*S*)-methyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-amide;
(*S,S*)-2-(3-Chloro-benzenesulfonylamino)-3-cyclohexyl-N-[1-methyl-2-(4-trifluoromethoxy-phenylamino)-ethyl]-propionamide;
(*S,S*)-3-Cyclohexyl-N-[1-methyl-2-(4-trifluoromethoxy-phenylamino)-ethyl]-2-(3-trifluoromethoxy-benzenesulfonylamino)-propionamide;
N-((*S*)-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)(cyclohexyl) methyl)-3-methylbenzamide;
N-((*S*)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(2-chlorophenyl)ethyl)-3-methylbenzamide;
N-((*S*)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(3-chlorophenyl)ethyl)-3-methylbenzamide;
N-((*S*)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(4-chlorophenyl)ethyl)-3-methylbenzamide;
(*S*)-N-{2-Cyclopentyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methyl-benzamide;
N-((*S*)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-3,3-dimethylbutyl)-3-methylbenzamide;
N-((*S*)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-3-cyclohexylpropyl)-3-methylbenzamide;
N-((*S*)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-phenylethyl)-3-methylbenzamide;
N(*R,S*)-((3-(5-fluoroindolin-1-yl)-1-hydroxypropan-2-(*R*)-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;
N(*S*)-((3-(benzyloxy)-1-(5-fluoroindolin-1-yl)propan-2-(*R*)-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;
(*R,S*)-N-((2-(5-fluoroindolin-1-yl)ethylcarbamoyl)(2,4-dichlorophenyl)methyl)-3-methylbenzamide;

(S,S)-N-((3-(5-fluoroindolin-1-yl)-1-hydroxypropan-2-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;
(S,S)-4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-[2-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(5-isoxazol-3-yl-thiophene-2-sulfonylamino)-propionamide;
(S)-2-(3-Biphenyl-4-yl-ureido)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(4-phenoxy-benzenesulfonylamino)-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(naphthalene-1-sulfonylamino)-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(4-trifluoromethyl-benzenesulfonylamino)-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(4-trifluoromethoxy-benzenesulfonylamino)-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-[4(4-fluorophenoxy)-benzenesulfonylamino]-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(4'-methoxy-biphenyl-4-sulfonylamino)-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(4-methoxy-benzenesulfonylamino)-propionamide;
(S)-3-Cyclohexyl-2-(4-difluoromethoxy-benzenesulfonylamino)-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-phenylmethanesulfonylamino-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(toluene-3-sulfonylamino)-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-[4(4-methoxyphenoxy)-benzenesulfonylamino]-propionamide;
(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(3-methoxy-benzenesulfonylamino)-propionamide;

(S,S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-methyl-ethyl]-2-(toluene-3-sulfonylamino)-propionamide;
(S,S)-3-[4,4-Dimethyl-2-(toluene-3-sulfonylamino)-pentanoylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid tert-butyl ester;
(S,S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-methyl-ethyl]-2-(3-trifluoromethoxy-benzenesulfonylamino)-propionamide;
(S,S)-2-(3-Chloro-benzenesulfonylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-methyl-ethyl]-propionamide;
(S,S)-N-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-yl)methyl]-3-hydroxy-propylcarbamoyl]-propyl}-3-methoxy-benzamide;
(S,S)-3-[4,4-Dimethyl-2-(toluene-3-sulfonylamino)-pentanoylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;
(S,S)-2-Benzenesulfonylamino-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-methyl-ethyl]-propionamide; and
(S,S)-4,4-Dimethyl-2-(toluene-3-sulfonylamino)-pentanoic acid [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-methyl-ethyl]-amide.